State Food and Drug Administration (FDA) Minister Rajendra Shingne on Friday said FDA officials have been instructed to check black marketing of remdesivir and tocilizumab — two drugs essential for treatment of COVID-19 patients — and ensure they are not sold at high prices.
Mr. Shingne, who chaired a meeting of manufacturers and distributors of both the medicines, said a toll-free number 1800222365 has been opened to lodge complaints regarding the black marketing of the medicines.
The State government also said the availability of the two drugs will be increased in the coming days as their production is set to rise. The State will also be making public the information on the rates and availability of all drugs used in the fight against novel coronavirus.
Officials said at present, both the drugs are manufactured outside Maharashtra. Remdesivir is manufactured at Hetero Healthcare in Hyderabad and Cipla in Goa, while tocilizumab is imported by M/s Rosch and Cipla distributes it.
The minister said since the import of tocilizumab is limited, there is an equivalent to it — itiozulmab from Biocon. “This other medicine can be used on doctor’s prescription. Since the medicines are in shortage, we have directed that these are used only for critical patients,” Mr. Shingne said.
He said production of remdesivir is set to increase from Gujarat through Hereto Healthcare. “Another company called M/s Moylon from Gujarat is also going to bring remdesivir in the market,” Mr. Shingne said.
You have reached your limit for free articles this month.
To get full access, please subscribe.
Already have an account ? Sign in
Show Less Plan
Subscription Benefits Include
Today's Paper
Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.
Faster pages
Move smoothly between articles as our pages load instantly.
Unlimited Access
Enjoy reading as many articles as you wish without any limitations.
Dashboard
A one-stop-shop for seeing the latest updates, and managing your preferences.
Personalised recommendations
A select list of articles that match your interests and tastes.
Briefing
We brief you on the latest and most important developments, three times a day.
*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.
A letter from the Editor
Dear subscriber,
Thank you!
Your support for our journalism is invaluable. It’s a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.
The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.
We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.
Suresh Nambath
